- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Terns Pharmaceuticals Inc (TERN)
Terns Pharmaceuticals Inc stock price live, this page displays NASDAQ TERN stock exchange data. View the TERN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Terns Pharmaceuticals Inc real time stock price chart below.
What Is the Terns Pharmaceuticals Inc Stock Price Today?
The Terns Pharmaceuticals Inc stock price today is 7.250.
What Is the Stock Symbol for Terns Pharmaceuticals Inc?
The stock symbol for Terns Pharmaceuticals Inc is ""TERN.""
What Stock Exchange Does Terns Pharmaceuticals Inc Trade On?
Terns Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Terns Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Terns Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TERN quote. (ISIN: US8808811074)
What Is the Terns Pharmaceuticals Inc Stock Price Today?
The Terns Pharmaceuticals Inc stock price today is 7.250.
What Is the Stock Symbol for Terns Pharmaceuticals Inc?
The stock symbol for Terns Pharmaceuticals Inc is ""TERN.""
What Stock Exchange Does Terns Pharmaceuticals Inc Trade On?
Terns Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Terns Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Terns Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TERN quote. (ISIN: US8808811074)
Fair Value
An estimate of a Terns Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.700
7.260
52 wk Range
1.865
11.400
TERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Terns Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.7007.260
52 wk Range
1.86511.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TERN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Terns Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
20.000
Upside
+175.86%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Terns Pharmaceuticals Inc Company Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Terns Pharmaceuticals Inc SWOT Analysis
Promising Pipeline | Terns Pharmaceuticals' lead candidates TERN-701 for CML and TERN-601 for obesity show potential in addressing significant unmet medical needs |
CML Treatment Edge | TERN-701 demonstrates favorable efficacy and safety profile in early trials, potentially differentiating it from existing CML treatments |
Obesity Market Entry | TERN-601, an oral GLP-1RA, positions Terns to compete in the expanding obesity treatment market, with Phase 2 trials set for Q2 2025 |
Financial Strength | With $334.3M in cash, funding operations into 2028, and analyst price targets ranging from $14 to $34, Terns shows strong financial positioning |
Compare TERN to Peers and Sector
Metrics to compare | TERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.9x | −0.9x | −0.6x | |
PEG Ratio | −0.34 | −0.01 | 0.00 | |
Price/Book | 2.1x | 1.8x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | 155.2% | 154.9% | 39.0% | |
Fair Value Upside | Unlock | −0.8% | 4.9% | Unlock |
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.000
(+175.86% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
-0.26 / -0.2918
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Terns Pharmaceuticals Trade On?
Terns Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Terns Pharmaceuticals?
The stock symbol for Terns Pharmaceuticals is "TERN."
What Is the Terns Pharmaceuticals Market Cap?
As of today, Terns Pharmaceuticals market cap is 632.27M.
What Is Terns Pharmaceuticals's Earnings Per Share (TTM)?
The Terns Pharmaceuticals EPS (TTM) is -1.04.
When Is the Next Terns Pharmaceuticals Earnings Date?
Terns Pharmaceuticals will release its next earnings report on 17 Nov 2025.
From a Technical Analysis Perspective, Is TERN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Terns Pharmaceuticals Stock Split?
Terns Pharmaceuticals has split 0 times.
How Many Employees Does Terns Pharmaceuticals Have?
Terns Pharmaceuticals has 59 employees.
What is the current trading status of Terns Pharmaceuticals (TERN)?
As of 26 Aug 2025, Terns Pharmaceuticals (TERN) is trading at a price of 7.25, with a previous close of 6.69. The stock has fluctuated within a day range of 6.70 to 7.26, while its 52-week range spans from 1.87 to 11.40.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.